We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has approved the first over-the-counter (OTC) naloxone nasal spray — Emergent BioSolutions’ opioid overdose therapy Narcan, 4 mg — and is encouraging other producers to apply for OTC status. Read More
Alio, a firm focused on wireless remote patient monitoring, has received FDA clearance to add potassium, hematocrit and hemoglobin monitoring to its non-invasive SmartPatch system.
The expanded approval is for patients who are at least 13 years old who cannot be effectively treated with continuous positive airway pressure (CPAP) therapy. Read More